Victory Medical Center Pharmacy
Registered Address: Texas, United States (United States)
Co-Packing Capabilities, Minimums & Certifications
Contract pharmaceuticals & sterile/otc drugs manufacturing in TX.
5 Questions to Ask Victory Medical Center Pharmacy Before Signing a Manufacturing Contract
Bring these exact questions to your discovery call with their QA Director or account rep before wiring a production deposit:
- Q1: On 2026-09-10, FDA cited 21 CFR 211.22(d) (Electronic Record Data Integrity (21 CFR Part 11) & Retention). Can your Quality Unit share the signed 15-day CAPA response and verification logs showing this gap is closed?
- Q2: On 2026-09-10, FDA cited 21 CFR 211.160(b) (Incoming Ingredient Identity Testing & COA Qualification). Can your Quality Unit share the signed 15-day CAPA response and verification logs showing this gap is closed?
- Q3: Do you perform 100% FTIR/HPLC identity testing on incoming active ingredients in-house (21 CFR 111.75(a)(1)), or do you rely on vendor COAs?
- Q4: Will you sign our Quality Agreement Rider requiring 24-hour notification if an FDA investigator issues a Form 482 or Form 483 at FEI 3010485868?
- Q5: Can we review a redacted Master Manufacturing Record (MMR) and Batch Production Record (BPR) with dual-operator weight verification and yield reconciliation?
Cross-Database Regulatory & Inspection Timeline
Unified chronological history across FDA ORA Inspections, Form 483s, Warning Letters, Enforcement Recalls, and OASIS Import Refusals.
FDA Form 483 issued to Victory Medical Center Pharmacy (FEI 3010485868) on 2026-09-10 following an inspection of its producer of sterile and non sterile drug products operations in Texas. The report documents 2 inspection observations centered on Electronic Record Data Integrity (21 CFR Part 11) & Retention, Incoming Ingredient Identity Testing & COA Qualification.
- 21 CFR 211.22(d) (Electronic Record Data Integrity (21 CFR Part 11) & Retention): Uncontrolled spreadsheets, shared laboratory logins, missing audit trails, backdated entries, or failure to retain batch and distribution records for the statutory window. REPEAT OBSERVATION
- 21 CFR 211.160(b) (Incoming Ingredient Identity Testing & COA Qualification): Failure to perform at least one test to verify the identity of every incoming dietary ingredient or raw component before use, or relying on a supplier's Certificate of Analysis (COA) without first qualifying the supplier.
FDA Demand: Provide a comprehensive independent assessment of your quality unit, complete batch record remediation plan, and retrospective stability/identity testing data within 15 working days.
Manufacturer Right-of-Reply & Free Match Correction
GUARDRAIL PROTECTEDTo ensure fairness and accuracy, facility owners may submit verified Form 483 closeout evidence, CAPA completion statements, or entity-resolution corrections free of charge. Sponsorship never alters an FDA Record Index score.
Following the 2026-09-10 inspection, our Quality Unit submitted a comprehensive CAPA response with third-party FTIR identity validation protocols and updated batch production records within 12 business days. All corrective actions are complete and verified.
6-Subsystem cGMP Radar Breakdown
Sub-scores mapped across FDA's six core inspection subsystems.
Verified AAA/AA Co-Packers in This Sector
Compare or request quotes from top-rated contract manufacturers with clean FDA inspection histories:
Score Provenance Receipts
Every point in this facility's FDA Record Index (64/100) is backed by a linked government record (36-month half-life decay).
| Event | Date | Weight | Receipt |
|---|---|---|---|
| Inspection Outcome (VAI) | 2026-09-10 | -9.7 pts | INSP-483-3010485868-20260910 ↗ |
| Form 483 (2 observations, 1 repeat) | 2026-09-10 | -8.7 pts | 483-3010485868-20260910 ↗ |
| Warning Letter (Closed Out) | 2026-07-15 | -9.3 pts | CMS-684100 ↗ |